Tharimmune Secures $540 Million in Post-IPO Financing on November 4, 2025

According to industry sources, Tharimmune secured $540 million in post-IPO financing on November 4, 2025. Investors in this round include Liberty City Ventures, DRW Venture Capital, leading exchanges, Polychain, and ARK Invest. With this transaction, Tharimmune’s cumulative financing total has reached $540 million.Tharimmune, Inc. (THAR) is a clinical-stage biotechnology company focused on developing a portfolio of therapeutic candidates targeting inflammation and immunology. This financing marks a significant milestone for the company in the capital markets and reflects sustained investor confidence in the biopharmaceutical sector, particularly in the field of immunotherapy. Notably, beyond advancing its core pharmaceutical R&D initiatives, Tharimmune intends to implement a cryptocurrency financing strategy and acquire the native token of Canton Network, Canton Coin (CC). This innovative approach underscores a new trend of traditional biotech firms integrating blockchain technology.Driven by the rising global prevalence of immune-related diseases, demand for inflammation and immunology treatments continues to grow. Tharimmune’s diversified financing strategy not only provides robust capital support for its clinical research but also serves as a reference case for novel funding models in the biopharmaceutical industry. This round brings together traditional venture capital firms, cryptocurrency trading platforms, and innovation-focused investment funds, demonstrating cross-sector capital recognition of the company’s development potential.